Lilly closed at $1,169.60, and one widely followed narrative pegs fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
Recap by typeshit. Full story at Yahoo Finance.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Eli Lilly released new data on pairing its psoriasis drug Taltz with tirzepatide in adults who have both conditions.
A post hoc MRI look at 55 people, shown at EASD 2026, found average liver fat dropped from 8.8% to 3.1% by week 72. No placebo comparison was reported.
Loading…